| TYRO3 |
TYRO3, BYK, DTK, RSE, SKY: Tyrosine-protein kinase receptor TYRO3 precursor |
LCK |
LCK: Proto-oncogene tyrosine-protein kinase LCK |
13.200 |
Evidence |
|
| SYK |
SYK: Tyrosine-protein kinase SYK |
TYRO3 |
TYRO3, BYK, DTK, RSE, SKY: Tyrosine-protein kinase receptor TYRO3 precursor |
13.200 |
Evidence |
|
| SH2D1A |
SH2D1A, DSHP, SAP: SH2 domain-containing protein 1A |
TEK |
TEK, TIE2: Angiopoietin-1 receptor precursor |
13.200 |
Evidence |
|
| SMAD2 |
SMAD2, MADH2, MADR2: Mothers against decapentaplegic homolog 2 |
MLLT7 |
IPI00654651 |
13.2 |
Evidence |
|
| FOXO1A |
FOXO1A, FKHR: Forkhead box protein O1A |
GCN5L2 |
GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 |
13.2 |
Evidence |
|
| GNA12 |
GNA12: Guanine nucleotide-binding protein alpha-12 subunit |
GRM1 |
GRM1, GPRC1A, MGLUR1: Metabotropic glutamate receptor 1 precursor |
13.2 |
Evidence |
|
| DAB2 |
DAB2, DOC2: Disabled homolog 2 |
CBLB |
CBLB, RNF56, Nbla00127: E3 ubiquitin-protein ligase CBL-B |
13.2 |
Evidence |
|
| LIMK1 |
LIMK1, LIMK: LIM domain kinase 1 |
SNF1LK2 |
SNF1LK2, KIAA0781, QIK: Serine/threonine-protein kinase SNF1-like kinase 2 |
13.2 |
Evidence |
|
| GSK3A |
GSK3A: Glycogen synthase kinase-3 alpha |
TIAM1 |
TIAM1: T-lymphoma invasion and metastasis-inducing protein 1 |
13.2 |
Evidence |
|
| PRKCI |
PRKCI, DXS1179E: Protein kinase C iota type |
PRKCZ |
PRKCZ, PKC2: Protein kinase C zeta type |
13.2 |
Evidence |
|
| MAPK1 |
MAPK1, ERK2, PRKM1, PRKM2: Mitogen-activated protein kinase 1 |
STMN2 |
STMN2, SCG10, SCGN10: Stathmin-2 |
13.2 |
Evidence |
|
| MAPK3 |
MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 |
BTK |
BTK, AGMX1, ATK, BPK: Tyrosine-protein kinase BTK |
13.2 |
Evidence |
|
| MAPK3 |
MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 |
SYK |
SYK: Tyrosine-protein kinase SYK |
13.2 |
Evidence |
|
| CCND1 |
CCND1, BCL1, PRAD1: G1/S-specific cyclin-D1 |
BRCA1 |
BRCA1, RNF53: Breast cancer type 1 susceptibility protein |
13.2 |
Evidence |
O
|
| CBL |
CBL, CBL2, RNF55: E3 ubiquitin-protein ligase CBL |
PRKCE |
PRKCE, PKCE: Protein kinase C epsilon type |
13.2 |
Evidence |
|
| CBL |
CBL, CBL2, RNF55: E3 ubiquitin-protein ligase CBL |
GSK3A |
GSK3A: Glycogen synthase kinase-3 alpha |
13.2 |
Evidence |
|
| OSBP |
OSBP, OSBP1: Oxysterol-binding protein 1 |
RIN1 |
RIN1: Ras and Rab interactor 1 |
13.2 |
Evidence |
|
| ATF1 |
ATF1: Cyclic AMP-dependent transcription factor ATF-1 |
GCN5L2 |
GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 |
13.2 |
Evidence |
|
| ATF1 |
ATF1: Cyclic AMP-dependent transcription factor ATF-1 |
MAPK3 |
MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 |
13.2 |
Evidence |
|
| VAV1 |
VAV1, VAV: Proto-oncogene vav |
MAPK3 |
MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 |
13.2 |
Evidence |
|
| VIL2 |
IPI00479359 |
GSK3A |
GSK3A: Glycogen synthase kinase-3 alpha |
13.2 |
Evidence |
|
| VDR |
VDR, NR1I1: Vitamin D3 receptor |
GCN5L2 |
GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 |
13.2 |
Evidence |
|
| FGR |
FGR, SRC2: Proto-oncogene tyrosine-protein kinase FGR |
CDK2 |
CDK2: Cell division protein kinase 2 |
13.2 |
Evidence |
|
| ERBB2 |
ERBB2, HER2, NEU, NGL: Receptor tyrosine-protein kinase erbB-2 precursor |
KIT |
KIT: Mast/stem cell growth factor receptor precursor |
13.2 |
Evidence |
|
| PAK4 |
PAK4, KIAA1142: Serine/threonine-protein kinase PAK 4 |
SOS1 |
SOS1: Son of sevenless homolog 1 |
13.2 |
Evidence |
|